Stockreport

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) f...

Immunovant, Inc.  (IMVT) 
PDF Pete Salzmann, M.D. retired from his role as Immunovant CEO and Director Leadership change is part of a broader strategic transition with Roivant increasing operation [Read more]